However, traditional approaches to regulatory intelligence – largely manual and reactive – are no longer sufficient to manage the pace, volume, and complexity of regulatory changes. Enter artificial intelligence (AI).

AI is fundamentally transforming how pharmaceutical companies approach regulatory intelligence. From automated monitoring of global health authority updates to predicting regulatory trends and accelerating submission planning, AI empowers regulatory teams to become more proactive, agile, and informed.

In this blog, we explore the transformative role of AI in advancing pharma regulatory intelligence, the technologies involved, and how companies can leverage it for better compliance and strategic advantage.

Understanding Regulatory Intelligence in Pharma

Regulatory intelligence refers to the systematic collection and analysis of regulatory information – such as guidelines, updates, submission requirements, and approval trends – relevant to product development and commercialization.

Effective RI supports:

• Product classification and pathway determination
• Country-specific submission planning
• Labeling strategy and compliance
• Risk mitigation and regulatory change management
• Competitor benchmarking and regulatory forecasting

But traditional RI methods rely heavily on human analysts sifting through vast amounts of data, leading to delays, missed updates, and inconsistent insights.

The AI Advantage in Regulatory Intelligence

AI brings speed, scale, and structure to the otherwise manual processes involved in regulatory intelligence. Here’s how:

1. Automated Monitoring of Regulatory Sources

AI can scan, extract, and categorize updates from hundreds of global health authority websites, databases, and publications – 24/7. Natural language processing (NLP) engines:

• Identify relevant changes in regulations or guidelines
• Classify updates by geography, product type, or therapeutic area
• Alert regulatory teams based on predefined relevance filters

This replaces manual monitoring and ensures no critical updates are missed.

2. Intelligent Search and Retrieval

Instead of manually combing through large documents, AI tools enable advanced semantic search:

• Ask natural language queries like “What are the latest EMA requirements for pediatric formulations?”
• Get accurate, summarized, and source-linked answers instantly
• Surface historical context, related regulations, and precedents

This improves research productivity and decision accuracy.

3. Predictive Regulatory Analytics

Machine learning models can identify patterns in regulatory approvals, deficiencies, and response timelines across regions and therapeutic areas. This enables:

• Forecasting submission timelines and approval probabilities
• Identifying regulatory bottlenecks before they occur
• Benchmarking performance against competitors

Predictive analytics empowers teams to make data-driven, forward-looking decisions rather than reacting to issues post-factum.

4. Regulatory Change Impact Analysis

AI engines can compare changes across document versions and assess downstream impacts on labeling, clinical protocols, CMC sections, or risk management plans.

This helps:

• Prioritize regulatory actions based on business impact
• Route changes to the appropriate SME or functional group
• Reduce the risk of non-compliance due to outdated content

Technologies Powering AI in Regulatory Intelligence

Several AI technologies work together to streamline and strengthen pharma RI:

By integrating these technologies into RI platforms, pharma companies can gain a deeper, faster, and more contextual understanding of the regulatory landscape.

Key Use Cases of AI-Powered Regulatory Intelligence

1. Global Regulatory Monitoring

Track and alert on relevant regulatory developments across FDA, EMA, PMDA, CDSCO, TGA, and more – automatically and in real time.

2. Submission Planning and Readiness

Understand country-specific requirements for eCTD, dossier format, module expectations, and timelines to accelerate planning.

3. Labeling Compliance

Monitor evolving labeling requirements, detect inconsistencies across markets, and flag necessary updates to maintain compliance.

4. Competitor Intelligence

Analyze competitor approval trends, regulatory strategies, and submission timelines using publicly available databases.

5. Risk Assessment and Scenario Planning

Use AI to model various regulatory pathways and assess risk under different regulatory regimes or product profiles.

Benefits of AI in Regulatory Intelligence

When scaled across the organization, these benefits translate to faster product development cycles, lower regulatory risk, and improved market access.

Overcoming Implementation Challenges

While the benefits of AI in regulatory intelligence are clear, successful adoption requires attention to:

• Data quality: AI models need access to accurate, structured data for meaningful insights.
• Integration: AI solutions should integrate with existing regulatory and quality systems (RIM, QMS, DMS).
• Human oversight: Regulatory experts should validate AI-generated insights and provide context-specific judgment.
• Change management: Training, communication, and executive buy-in are key to adoption across global teams.

Partnering with an experienced provider like DDi helps organizations navigate these challenges with pre-built frameworks, domain-trained AI models, and pharma-specific implementation expertise.

The Future of Regulatory Intelligence is AI-Driven

As regulatory agencies themselves begin embracing AI (e.g., the FDA’s Project ProACT), pharma companies must evolve to stay ahead. The future of regulatory intelligence will be:

• Real-time instead of retrospective
• Predictive instead of reactive
• Connected across regions and functions
• Self-learning through feedback loops and automation

Forward-thinking regulatory affairs teams that embrace AI today will not only be more compliant – but also more competitive and innovation-ready.

Conclusion: A Smarter Way to Navigate Regulatory Complexity

The pharmaceutical regulatory landscape is only becoming more complex and dynamic. Traditional methods of managing regulatory intelligence are no longer sufficient for organizations that aim to move fast, scale globally, and reduce compliance risk.

AI offers a new paradigm – one that transforms static information into dynamic insights, streamlines regulatory operations, and equips teams with the tools they need to anticipate and act.

Whether you’re tracking global health authority updates, optimizing submission strategies, or staying ahead of evolving labeling requirements, AI-powered regulatory intelligence is the smart way forward.

Ready to Upgrade Your Regulatory Intelligence with AI?

DDi helps pharma and biotech companies gain a competitive edge through AI-driven regulatory intelligence. From automated global monitoring to predictive insights and workflow integration, our solutions are built for compliance, speed, and scale.

Explore how DDi can transform your regulatory operations.

To increase flexibility on their teams, regulatory managers need guidance, tools and support otherwise, they could burn out on the job or check out to find a new one. Here are 3 ways managers can offer their teams flexibility without breaking under the coordination costs or significantly stalling progress.

Rethink When your Team Work Together

For complex tasks that require teamwork, it’s not feasible to provide your teams with complete flexibility (i.e., the ability to work for any duration at any time). However, returning to the standard in-office work week won’t work either. Thus, managers will need to think differently and deeply about project requirements and schedule accordingly.

For project-based workflows, managers should carefully chart out the project tasks and timeline and issue an advance request for employees to block a specific set of days for overlapping work during key project phases. Leverage tools and technology to make this process more efficient.

Rethink Information Sharing

When team were co-located and working roughly similar hours, it was easier to keep everyone on the same page with meetings and learn about important issues by walkingaround. Giving or receiving an important update only required a few steps (or perhaps a brief elevator ride).

Long waits for status updates or answers to questions can kill productivity. Thus, information availability is critical for flexible workplaces. There are good tools (be it RIM or RPMregulatory Process Management system or Automation) to facilitate asynchronous work. However, teams must actually use and update them in real time. For example, posting a completed document or global registration update or HA approval to a shared repository after few weeks of work won’t cut it. As members may not be available for hours or even days, having access to in-progress work is of paramount importance. Cloud based tools that manage documents and data make these easy.

Revisit What your Teams Are Working On

Combining and expanding on the previous two steps, regulatory managers must think more deeply than ever about the structure of their employees’ tasks and priorities. Map out each part of the task and how they’re connected to one another to determine when scheduling bursts will be needed and when you can assign discrete pieces of the project to smaller subgroups. Record and update all of this information in a shared system (like a RIM or RPM system).

Understanding the connections between different tasks is especially crucial for setting priorities to avoid bottlenecks. If everything is a priority, nothing is a priority. Frequently and clearly communicating priorities (with help of available tools) will help ensure that your teams’ time and efforts are well spent, no matter when or where they’re working.

If regulatory teams want the benefits of flexibility, they’ll also need to shoulder some of the responsibility that goes with it, like autonomous problem-solving and providing and checking for updates in systems. Regulatory Managers are still responsible for making sure everyone is rowing to the correct location in the same direction even if they’re rowing at different times. Utilize tools like ViSU to help accomplish the global norm (or remote, flexibility, etc) that Covid set for all companies and Regulatory function is no exception.

According to Gartner, Innovation leaders lack a defined strategy to scale automation with tactical and strategic goals. They must deliver end-to-end automation beyond

RPA by combining complementary technologies to augment business processes.

Gartner calls this “Hyperautomation”.

How can enterprises define a winning automation strategy, combine Digital Ops tools, and augment business processes for agility and scale?

Gartner analysts Saikat Ray, Cathy Tornbohm, Marc Kerremans, and Derek Miers have authored a paper that examines the key challenges of hyper automation and how to optimize for success.

The Do’s

1. Be Willing to Change

Clinical Supplies organizations those who wants to establish a better RTSM for the first time must have appropriate conventional paper system for inventories, labeling process, and clinical supply approvals. By implementing electronic system for clinical supplies; organization can reorient the traditional method to person’s role based process and also can optimize the over all flow that is following till now. The new system of electronically approval of supplies and labels has capability to motivate overall work process. A complete/mutual support of other organizations like Clinical, Regulatory, Quality, and Clinical Supplies is much more needed for implementation and validation of this new electronic system. Apart from this, it also needs internal departments involving in the systems rollout support/coordination is required to move forward. Even after getting support from all departments, other employees – organization must rethink about this new system’s impact on already established company’s clinical processes and other electronic systems. To validate this agenda subject matter expert in the same field need to evaluate and analyze for the best output.

2. High Emphasis on Training

Training the manpower will become difficult task when no employee has little or nil knowledge about the electronic RTSM. All the staff from different departments like quality, regulatory, label, inventory, clinical supplies manager, administrator in the system flow must need appropriate role specific training and hands on experience to yield excellent product outcome. It is recommended to provide training for all the employees with specific roles just before two to four weeks of launching the system. So that they can be easily involved in validate testing, if someone feels uneasy they can be given with the refresher training once again to adopt the system more comfortably. The training is time sensitive since this electronic system is a complex process and always it is advised to give training close to the system deployment date, then only individual will not forget the learned skills and apply the same to get quick hands on experience

3. Follow a Uniform Naming Convention for All Meta Data

Data security is very important while following the new electronic system and it is suggestible to implement uniformity in naming convention of all the departments. A typical planning and thought process of naming convention is mandatory for all the labels, security models, supplies, materials, and kits. For instance naming convention could have study numbers, study names, franchises, regulatory classification like RX/OTC etc.., so the naming and security model should be confidential. This privacy will help the organization to secure/protect the data, and limit the access to roles only for those who are interacting with it. All this data security, planning, limited access is not a simple thought but should be determined before implementing the RTSM in the organization.

The Don’ts

1. Do not Recreate Paper Based RTSM in the New Electronic System

The conventional method of paper based inventory and clinical supplies release process is a decades old method which was entangled with departments and individuals. A general mistake of following the same rules of paper system with limitations and faults while implementing the new electronic RTSM will be done by many organizations. It should not be repeated but need a brainstorm and optimization of clinical supplies management at the planning phase of the project in organization. Also make a plan in creating maps, approval process, labeling process etc., must feed into the system and validate the clinical supplies system prior to the implementation of RTSM.

2. Minimize the Customization of RTSM Tool

Electronic clinical supplies management systems are built with advanced IT technology for best practices. The software can setup in many ways with multiple configuration options like approvals, routes, locations, security, and metadata. All the organizations are advised to minimize the customization and make use of available configurations to avoid complications, process delays with the tool. Custom code implementation in the RTSM is expensive, difficult to validate and maintain, also need much effort. If the customized systems are launched, performance up gradation and module changes will become costly and time consuming process, similarly more chances of getting errors in the system will occur.

3. Put joint efforts of IT and clinical supplies group

Different in opinions will cause damage to any organization, usually Information Technology (IT) and clinical supplies departments will have difference perspectives. Before launching the new electronic RTSM tool; a joint effort of IT and clinical supplies departments would make the tool successful and give best results for the organization. IT group works on running maintaining the database, security, hardware, network privileges, granting access to different roles, and restricting them on need base. Where as clinical supplies group works on engaging neutral third party consultants, brining them to harmonized agreement processes, generating labels, getting sample status, and analyzing quality of metadata. Mutual communication and understanding between the two departments can make use of the RTSM in a far better way to get more business and profits for the organization. Another key point to remember is – third party consultants should to be a subject matter expert who must aware of best practices and processes that are compliant for RTSM.

MDR addresses the possibility that EUDAMED is not fully functional on the date of application of the MDR (26 May 2021). Until EUDAMED is fully functional, the MDR stipulates that the corresponding provisions of Directives 90/385/EEC4 and 93/42/EEC5 shall continue to apply for the purpose of meeting the obligations regarding the exchange of information.

Alternative solutions to submit and/or exchange information (as required under the MDR)

1.Device Registration:

Manufacturers should refer to the national provisions in Member States establishing product registration schemes. Obligation of UDI assignment (Basic UDI and UDI-DI) to a device applies from 26 May 2021 and Labelling requirements apply gradually, starting from 26 May 2021.

2. Registration of manufacturers , authorised representative s and importers

Manufacturers, authorised representatives and importers should refer to the national provisions in Member States. Please refer to MDCG Position Paper on the use of the EUDAMED actor registration module and of the Single Registration Number (SRN) in the Member States.

3. Summary of safety and clinical performance

The SSCP shall be made available to the public upon request without undue delay or the manufacturer shall specify where it is made available to the public. As soon as the functionality is available in Eudamed, the system may be used for the upload of the SSCP even before the notice of full functionality of Eudamed has been published.

4. Certificate of Conformity

Certificates will be made available upon request or will be uploaded in the national system where required.

5. Application for clinical investigations

The application for clinical investigations should take place via the respective national procedures applicable to clinical investigations.

6. CircaBC Centre for Administrations, Businesses and Citizens)

The Commission has made available the list to Member States by means of a dedicated secure directory in the Communication and Information Resources Centre for Administrations, Businesses and Citizens (CircaBC). It is used for following purpose…

• Nomination of experts for joint assessment of applications for notification
• Changes to designations and notifications
• Involvement of notified bodies in conformity assessment procedures
• Clinical evaluation consultation procedure for certain class III and class IIb devices
• Mechanism for scrutiny of conformity assessments of certain class III and class IIb devices
• Market surveillance activities